NCT04361565

Brief Summary

A novel coronavirus SARS-CoV-2 HAS arose in 2019 in Wuhan, China. Beside the classical semiology of this infection, numerous patients described olfactory and teste disorders. These symptoms are not described in this coronavirus, neurotropism of coronaviridae has been documented before. The aim of the study is to evaluate prevalence of anosmia and dysgeusia (olfactory and taste disorders) in coronavirus diagnosed patients and compare with different clinical conditions. The second endpoint is to evaluate the duration of these symptoms in order to better understand the semiology of this infection.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
81

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Mar 2020

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 20, 2020

Completed
21 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 10, 2020

Completed
12 days until next milestone

First Submitted

Initial submission to the registry

April 22, 2020

Completed
2 days until next milestone

First Posted

Study publicly available on registry

April 24, 2020

Completed
8 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2020

Completed
Last Updated

February 18, 2025

Status Verified

February 1, 2025

Enrollment Period

21 days

First QC Date

April 22, 2020

Last Update Submit

February 14, 2025

Conditions

COVID-19 by SARS-CoV-2 Infection

Outcome Measures

Primary Outcomes (3)

  • Anosmia

    Prevalence for anosmia in the COVID-19 + patients

    45 days

  • Ageusia

    Prevalence for ageusia in the COVID-19 + patients

    45 days

  • Duration of the loss of anosmia ageusia

    Duration measured in days

    45 days

Study Arms (1)

Individuals diagnosed for COVID-19

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Individuals that responded to a online form

You may qualify if:

  • COVID-19 diagnosed

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

CHU de Nice

Nice, France

Location

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 22, 2020

First Posted

April 24, 2020

Study Start

March 20, 2020

Primary Completion

April 10, 2020

Study Completion

December 31, 2020

Last Updated

February 18, 2025

Record last verified: 2025-02

Locations

FR(1)